The trading price of Chimerix Inc. (NASDAQ:CMRX) closed higher on Tuesday, May 23, closing at $1.43, 2.14% higher than its previous close.
Traders who pay close attention to intraday price movement should know that it fluctuated between $1.39 and $1.51. The company’s P/E ratio in the trailing 12-month period was 0.71, while its 5Y monthly beta was 1.15. In examining the 52-week price action we see that the stock hit a 52-week high of $2.90 and a 52-week low of $1.09. Over the past month, the stock has gained 21.19% in value.
Top 5 EV Tech Stocks to Buy for 2023
According a new report published by BloombergNEF on investment in the energy transition, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now.
Click Here to Download the FREE Report.
Sponsored
Chimerix Inc., whose market valuation is $117.23 million at the time of this writing, is expected to release its quarterly earnings report Aug 07, 2023 – Aug 11, 2023. Investors’ optimism about the company’s current quarter earnings report is understandable. Analysts have predicted the quarterly earnings per share to grow by -$0.24 per share this quarter, however they have predicted annual earnings per share of -$0.97 for 2023 and -$0.83 for 2024. It means analysts are expecting annual earnings per share growth of -150.00% this year and 14.40% next year.
The average estimate suggests sales will likely down by -40.90% this quarter compared to what was recorded in the comparable quarter last year. From the analysts’ viewpoint, the consensus estimate for the company’s annual revenue in 2023 is $910k. The company’s revenue is forecast to drop by -97.30% over what it did in 2023.
A company’s earnings reviews provide a brief indication of a stock’s direction in the short term, where in the case of Chimerix Inc. No upward and no downward comments were posted in the last 7 days. On the technical side, indicators suggest CMRX has a 50% Sell on average for the short term. According to the data of the stock’s medium term indicators, the stock is currently averaging as a 50% Sell, while an average of long term indicators suggests that the stock is currently 100% Sell.
Here is the average analyst rating on the stock as represented by 1.00 to 5.00, with the extremes of 1.00 and 5.00 suggesting the stock should be considered as either strong buy or strong sell respectively. The number of analysts that have assigned CMRX a recommendation rating is 7. Out of them, 0 rate it a Hold, while 5 recommend Buy, whereas 2 assign an Overweight rating. 0 analyst(s) have tagged Chimerix Inc. (CMRX) as Underweight, while 0 advise Sell. Analysts have rated the stock Buy, likely urging investors to take advantage of the opportunity to add to their holdings of the company’s shares.
A quick review shows that CMRX’s price is currently 23.73% off the SMA20 and 18.00% off the SMA50. The RSI metric on the 14-day chart is currently showing 71.37, and weekly volatility stands at 8.92%. When measured over the past 30 days, the indicator reaches 5.36%. Chimerix Inc. (NASDAQ:CMRX)’s beta value is currently sitting at 1.16, while the Average True Range indicator is currently displaying 0.07. With analysts defining $5.00-$11.00 as the low and high price targets, we arrive at a consensus price target of $7.29 for the trailing 12-month period. The current price is about -249.65% off the estimated low and -669.23% off the forecast high, based on this estimate. Investors will be thrilled if CMRX’s share price rises to $7.00, which is the median consensus price. At that level, CMRX’s share price would be -389.51% below current price.
To see how Chimerix Inc. stock has been performing in comparison to its peers in the industry, here are the numbers: CMRX stock’s performance was 2.14% in the latest trading, and -39.15% in the past year, while SIGA Technologies Inc. (SIGA) has traded 2.32% on the day and positioned -49.98% lower than it was a year ago. Another comparable company Johnson & Johnson (JNJ) saw its stock close -0.04% lower in the most recent trading session but was down -11.40% in a year. Furthermore, Emergent BioSolutions Inc. (EBS) showed an increase of 1.98% on the day while its price kept declining at -75.26% over the past year. Chimerix Inc. has a P/E ratio of 0.71, compared to SIGA Technologies Inc.’s 12.59 and Johnson & Johnson’s 32.81. Also in last trading session, the S&P 500 Index has plunged -1.12%, while the Dow Jones Industrial also saw a negative session, down -0.69% on the day.
An evaluation of the daily trading volume of Chimerix Inc. (NASDAQ:CMRX) indicates that the 3-month average is 913.68K. However, this figure has increased over the past 10 days to an average of 1.86 million.
Currently, records show that 88.30 million of the company’s shares remain outstanding. The insiders hold 0.80% of outstanding shares, whereas institutions hold 62.30%. The stats also highlight that short interest as of Apr 27, 2023, stood at 4.1 million shares, resulting in a short ratio of 5.59 at that time. From this, we can conclude that short interest is 4.63% of the company’s total outstanding shares. It is noteworthy that short shares in April were up slightly from the previous month’s figure, which was 3.79 million. However, since the stock’s price has seen -23.12% year-to-date, investors’ interest is likely to be reignited due to its potential to move even lower.
